Shopping Cart
- Remove All
- Your shopping cart is currently empty
3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κB activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $345 | Backorder | |
10 mg | $589 | Backorder | |
50 mg | $2,050 | Backorder |
Description | 3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κB activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide. |
In vitro | 3,4-DAA can alleviate the severity of colitis by inhibiting the response of Th1 cells, promoting the expression of Th2 cytokines, and inducing the expression of CD4(+)CD25(+) T cells[1]. |
In vivo | 3,4-DAA is an orally active synthetic derivative of the tryptophan metabolite anthranilic acid, which can reverse paralysis in mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS)[1]. |
Molecular Weight | 343.33 |
Formula | C18H17NO6 |
Cas No. | 2117759-07-4 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 5 mg/mL (14.56 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.